Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report)’s stock price hit a new 52-week high on Wednesday. The company traded as high as $84.00 and last traded at $84.00, with a volume of 10 shares. The stock had previously closed at $77.40.
Basilea Pharmaceutica Stock Performance
The company has a quick ratio of 5.97, a current ratio of 6.60 and a debt-to-equity ratio of 0.44. The stock has a fifty day moving average of $77.02 and a 200-day moving average of $69.95.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships.
Read More
- Five stocks we like better than Basilea Pharmaceutica
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
